FDA Audit Preparation

Similar documents
FDA Audit Preparation

Quality Assurance QA STANDARD OPERATING PROCEDURE FOR FDA or Pharmaceutical Sponsored Audits

Human Research Audit Program. Gabrielle Gaspard, MPH, CCRC Assistant Director, Human Research Compliance

Standard Operating Procedures Guidelines for Good Clinical Practice

Multi-Site Coordination Process. Drafted by: Ester Dimayuga Page 1 of 18

Source And Regulatory Documentation for DMID Clinical Studies

FDA Sponsor and Investigator Responsibility Checklist

Investigator-Initiated INDs

Objectives Discuss the importance of proper data collection. Identify the types of data collected for clinical trials. List potential source documents

3.1. Overall Principal Investigator (PI), who holds the IND and is the Sponsor.

Human Research Protection Program Good Clinical Practice Guidance for Investigators Regulatory File Essential Documents

PHARMACY, MEDICINES & POISONS BOARD

Introduction to Clinical Research

Source Documents and Regulatory Binders October 6, 2016

CANCER CENTER SCIENTIFIC REVIEW COMMITTEE

Audit and Regulatory Inspection Nopanan Yaibuathes Clinical Research and Compliance Manager Roche Thailand Ltd.

Study Start-Up SS STANDARD OPERATING PROCEDURE FOR Investigator Selection

Quality Assurance for the Research Team: Connecting Day-to-Day Operations to a Regulatory Framework

IRB-GCP and Timelines. Andrew Majewski, MSc. 1 st DOLF Meeting Washington University School of Medicine St Louis, Missouri-USA October th, 2010

Preparing for a United States Food and Drug Administration (FDA) Inspection: VOICE

GCP Basics - refresher

VCU Faculty Held IND and IDE Procedure Handbook

\\NAS1\George\Docs\SoCRA\CCRP communications\study guide management

National Institute of Allergy and Infectious Diseases National Institutes of Health Department of Health and Human Services

ClinicalTrials.gov Registration Guide

DRUG ORDERING AND MAINTENANCE

1.4 Applicable Regulatory Requirement(s) Any law(s) and regulation(s) addressing the conduct of clinical trials of investigational products.

Expanded Access and the Individual Patient IND

Good Clinical Practice

The European Medicines Agency Inspections ANNEX IV TO PROCEDURE FOR CONDUCTING GCP INSPECTIONS REQUESTED BY THE EMEA:

Maintaining your Investigational Device Exemption (IDE) with the FDA: Keys for Success. Jenna Stump, MS, CCRP Clinical Research Regulatory Specialist

Investigational Medicinal Product (IMP) Management Standard Operating Procedure

Obtaining Pre-Study Approvals for Clinical Trials K-30 Module 5 Navigating the Pre-Award Process

SWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL STUDY PROTOCOL CHAPTER 14 REVISED: OCTOBER 2015

Preparing your Audit Response Communication with the Central Office

The purpose of these guidelines is to describe a standardized approach for the management of

STANDARD OPERATING PROCEDURE

Trial Master File / Investigator Site File Index Clinical Trials of Investigational Medicinal Products

Office for Human Subject Protection. University of Rochester

Inspections: an academic perspective

Expanded Access. to Investigational Drugs & Biologics. for Treatment Use

Data Quality and Integrity: From Clinical Monitoring to Marketing Approval

Study Files and Filing

APPLICATION INSTRUCTIONS INSTITUTIONAL REVIEW BOARD. Revised January 2010 Page 1

Objectives. The Regulatory Binder = Investigator Site File= Trial Center File 8/16/2010. Essential Documents: Maintaining the Site's Regulatory Binder

Preparing for Close-Out of Studies and Sites

Standard Operating Procedures (SOPs) for. Clinical Research Personnel Part 16. Summary

Food and Drug Administration Guidance: Supervisory Responsibilities of Investigators

HUMAN GENETICS INITIATIVE

THE INDEPENDENT PHARMACIST S GUIDE TO THE ON-SITE AUDIT Amanda C. Fields, General Counsel for American Pharmacies (APRx) American Pharmacies 2011

Recommendations for Strengthening the Investigator Site Community

Work Instruction - Research Billing Risk

GCP Refresher and GCP/GCDMP Trends. in the CTN. Denise King, MS, RD, CCRA & Lauren Yesko, BS. Presented by:

Ethics Committees/IRBs Today: Challenges for Efficiency and Quality

Clinical Trials Management for Molecular Diagnostics. April 2016

Fourth Annual Pharmaceutical Regulatory and Compliance Congress

1 The Clinical Research Coordinator (CRC)... 1

Quality Assurance in Clinical Trials Introduction

Medicare and Medicaid Audits

REGULATORY ISSUES: HOW TO APPLY FOR AN IND. Penny Jester and Maaike Everts

Your Guide to the Compliance Process

RESEARCH PERFORMANCE SITES AND COLLABORATIVE OFF-SITE RESEARCH

IMP Management and Accountability

ICH/GCP Guidelines Self-Evaluation Questionnaire

Managing a Research Team. Mandy Morneault Manager, Research Coordinator Core ITHS Clinical Services

IRB Considerations for Investigator-Initiated Research

Quality Assurance in Clinical Trials

R&D Manager Hillingdon Hospital. Revision History Effective Date Reason For Change. recommendations Version no:

SERIOUS ADVERSE EVENTS

Human Research Protection Program. Investigator Manual

The Research Services Organization (RSO) of the Academic Health Center

Clinical Trials and the Code of Federal Regulations. Darlene Kitterman, MBA Director, Investigator Support & Integration Services September 24, 2014

Expedited Reporting. Darlene Kitterman, MBA Director, Investigator Support & Integration Services, OCTRI September 25, 2014

Good Clinical Practice (GCP) & Clinical Trial Registries

EIGHT BASIC ELEMENTS OF INFORMED CONSENT

GCP Convergence Improves Transportability of Medical Device Clinical Data

H-20 Page 1 of 5. Institutional Review Board Policy Manual HUMANITARIAN USE DEVICE (HUD) REQUIREMENTS

European Academy of Hospital Pharmacy Biotechnology Educational Summit. Clinical trials David Gerrett (Acknowledgment Mark Howells)

ANNEX. CHAPTER I General principles

Allergan plc COMPREHENSIVE COMPLIANCE PROGRAM

Standard Operating Procedure for Archiving

Outline of Discussion

10-CBA providing access to unlicensed cord blood units

10/9/2012. Alicia Joy, IRB. Wednesday October 10, Please be sure to sign in and take copies of each handout.

Triple C Housing, Inc. Compliance Plan

Clinical trials from CRA s point of view

SITE SUBMISSION FORM (SINGLE SITE)

ISRCTN: EudraCT Number: Sponsor Protocol Number: UCL 08/0350. Pharmacy Manual

Volunteering for Clinical Trials

Topics. Safety First Initiative. Drug Safety Communications DRUG SAFETY INITIATIVES AT THE FOOD AND DRUG ADMINISTRATION

MEDICAL DEVICE CLINICAL INVESTIGATIONS AND ISO 14155

Agency and Internal Labeling

Applicability of US Regulations to Canadian Research

5 th Training Workshop for Micro-, Small- and Medium- Sized Enterprises (SMEs)

GUIDELINE REGARDING COLLECTION, VERIFICATION, AND SUBMISSION OF THE REPORTS OF ADVERSE EVENTS / REACTIONS OCCURRING IN CLINICAL DRUG TRIALS

10/17/2016. Learning Objectives. What is Drug Accountability. Patricia Novo, MPA, MPH Beth Jeffries, BS, CCRP

Expanded Access (including Emergency Use & Humanitarian Use Devices)

PROTOCOL DRAFTING GUIDE

Streamlining IRB Procedures for Expanded Access

Recruitment Innovation Initiative

Transcription:

Duke University Office of Audit, Risk and Compliance (OARC) FDA Audit Preparation Margaret M. Groves, JD, CRA, CCRP, CHRC Associate Compliance Officer, Research Compliance Assurance (RCA)

External audits Agenda Best practices to get ready for audits 2

External Audits Food and Drug Administration Office of Human Research Protections Office of Inspector General 3

What to do when the FDA calls to schedule a site visit Obtain the following information: Call date Starting date of audit and expected duration Name of the person making the call Telephone number for questions FDA Investigator contact information/title Additional FDA Investigators names? 4

Ask Questions Who / what is being inspected? Wait for specific answers. Do not make suggestions. Which clinical trial/study? Principal Investigator/Co-Investigator(s)? Other details? Why is the inspection being done? Wait for the answer. Do not make suggestions. Routine (i.e. IND)? Directed (for cause)? Follow-up (i.e. 483; warning letter)? 5

Other Details? Does the FDA want specific personnel available? If yes, then list Who/When? Does the FDA want specific documents available? If yes, then list Does the FDA want any of these documents sent prior to their arrival? How? Send to overnight registered address? Use certified mail. Delivery by when? 6

What should I do first? Please immediately send notification to the following individual in the Office of Audit, Risk and Compliance: Margaret Groves, JD, CRA, CCRP, CHRC, Associate Compliance Officer for RCA Margaret.groves@duke.edu / 919-684-3133 7

General Preparation Notify parties involved with your study Sponsor (if required) Study team CRU IRB University Counsel s Office Pharmacy (if applicable) Laboratories (if applicable) Medical Records (if applicable) 8

General Preparation (cont d) Respond in an appropriate and timely fashion Request necessary medical records and/or electronic case report form access Reserve workspace for reviewer/auditor Arrange for a large table, as well as phone and copier access 9

Organize Files Regulatory Protocol (all versions) Investigator Brochure (all versions) Protocol Amendments FDA Form 1571/1572 (all versions) Investigator Agreements CVs for PI and Staff Medical Licenses IND/IDE Documents Enrollment/Screening Logs Delegation of Authority Log Drug Package Insert (if applicable) 10

Organize Files (cont d) IRB Files Approval Letter for Initial Protocol with Original Consent Form All Continuing Review Approval Letters and Original Updated Consent Forms All Amendment Approvals All Versions of Consent Documents for Screened and Enrolled Subjects All Status/Progress Reports for: IRB Approved Renewal(s) Adverse Events Deaths Study Termination Final Summary 11

Organize Files (cont d) Correspondence and Phone Logs All Sponsor Correspondence All CRO Correspondence (if applicable) All FDA Correspondence All IRB Correspondence Monitoring and Auditing Logs 12

Organize Files (cont d) Laboratory Laboratory Certification and Normal Ranges Up to Date CV of Laboratory Director Research Test Article Accountability Receipt Log Dispensing Log Return and Destruction Log Storage Temperature Log 13

Organize Files (cont d) Subject Documentation Complete Case Report Forms for Each Subject Enrolled Complete Source Documents for Each Subject Enrolled Verification of Inclusion/Exclusion Criteria Contact DOCR to Request Limited Access to MaestroCare for FDA 14

Day of the Review Have the following personnel available to the auditor: Routine Audit : Study Staff For Cause Audit Study Staff OARC - RCA Office Representative Ask to see 482 Notice of Inspection and auditor s credentials 15

Responding to FDA: On-Site Conduct Be concise, direct, and truthful Answer only questions asked, do not volunteer information Ask for clarification if you do not understand a question If you don t know an answer, say so, don t guess Tell the auditor if you later realize you gave incorrect information Ensure that all staff are educated on proper conduct during an FDA Inspection. 16

On-Site Conduct (cont d) Be available to answer questions or arrange logistics if interviews are requested Take notes on questions auditor asks Make duplicate copies of all documents that auditor requests to be copied Routine Audit: Provide daily reports to study team, RCA and CRU For Cause Audit: add IRB leadership, Vice Dean for Research, Chief Compliance Officer, and Associate Dean for Clinical Research to daily report distribution 17

FDA Audit Plan Review of Each Subject Enrolled or Possibly Only Those Chosen for Review Are case report forms complete for each subject? Are data collection forms complete? Are inclusion/ exclusion criteria documented? 18

FDA Audit Plan (cont d) Review of Source Documentation for Each Subject Enrolled that Documents the Following: Condition of the Subject at the Time of Entry (Inclusion/ Exclusion Criteria) Exposure to Research Article Concomitant Medications Clinical Assessments of the Subject During the Study Laboratory Reports Diagnostic Tests Dose Modification Adverse Events/Deaths Protocol Exemptions Early Termination 19

FDA Audit Plan (cont d) Review of Files/Logs Regulatory IRB Correspondence and Phone Logs Laboratory Research Test Article 20

FDA Audit Plan (cont d) At the conclusion of the on site review, there will be an Exit Meeting: Typical Findings No Actions Indicated Voluntary Actions Indicated FDA 483 Inspectional Observations If you receive a 483, please call OARC RCA section immediately so that we can assist you with your responses! 21

Compliance Program Advisory Role Not Just about Human Subject/Financial Compliance Reviews, Ethics and Compliance Monitoring or Privacy A Source of Information and Guidance on all Compliance Areas Prevention of Future Compliance Problems through Education Educational Compliance Reviews University Compliance Monitoring 22

Reporting Compliance Concerns Contact the Compliance Program: Duke Health Integrity Line: 1-800-826-8109 Duke University Compliance and Fraud Hotline 1-800-849-9793 Compliance concerns can be reported anonymously Non-retaliation and non-retribution policy OARC Research Compliance Assurance RCA@duke.edu https://oarc.duke.edu/compliance 23